Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Hay

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 9, 2018
Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER studyMartin J Scott, Hua Xiang, Daniel P Hart, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 13, 2015
In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiencyG N Pike, A M Cumming, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 5, 2012
Difficult clinical challenges in haemophilia: international experiential perspectivesAngela L Forsyth, Paul Giangrande, Charles R M Hay, et al.
Thrombosis Research|January 4, 2011
EUHASS: The European Haemophilia Safety Surveillance systemM Makris, G Calizzani, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2014
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparisonC R M Hay, B P Palmer, E A Chalmers, et al.
Expert Opinion on Biological Therapy|February 17, 2009
Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia AAmy Shapiro, Ralph Gruppo, Ingrid Pabinger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 20, 2017
Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical proceduresN Zozulya, C M Kessler, A Klukowska, et al.
Blood|October 24, 2014
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Peter W Collins, Benedict P Palmer, Elizabeth A Chalmers, et al.
Blood|October 19, 2006
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' OrganisationPeter W Collins, Sybil Hirsch, Trevor P Baglin, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 9, 2018
Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER studyMartin J Scott, Hua Xiang, Daniel P Hart, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 13, 2015
In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiencyG N Pike, A M Cumming, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 5, 2012
Difficult clinical challenges in haemophilia: international experiential perspectivesAngela L Forsyth, Paul Giangrande, Charles R M Hay, et al.
Thrombosis Research|January 4, 2011
EUHASS: The European Haemophilia Safety Surveillance systemM Makris, G Calizzani, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2014
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparisonC R M Hay, B P Palmer, E A Chalmers, et al.
Expert Opinion on Biological Therapy|February 17, 2009
Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia AAmy Shapiro, Ralph Gruppo, Ingrid Pabinger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 20, 2017
Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical proceduresN Zozulya, C M Kessler, A Klukowska, et al.
Blood|October 24, 2014
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Peter W Collins, Benedict P Palmer, Elizabeth A Chalmers, et al.
Blood|October 19, 2006
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' OrganisationPeter W Collins, Sybil Hirsch, Trevor P Baglin, et al.
Pageof 6